CU-CPT9a

CU-CPT9a is a drug which acts as a potent and selective antagonist of Toll-like receptor 8 (TLR8), with an IC₅₀ of 0.5nM. Activation of toll-like receptors triggers release of cytokines and other signalling factors, leading to inflammation. This is an essential part of the immune system's response to infection, but chronic activation of TLR signalling is thought to be involved in various inflammatory and autoimmune disorders. CU-CPT9a has immunosuppressant properties, and may have applications in the treatment of autoimmune disorders, as well as being used in scientific research into the function of TLR8.^{[1][2][3][4][5]}

CU-CPT9a

Identifiers
IUPAC name 4-(7-methoxyquinolin-4-yl)-2-methylphenol
CAS Number	2165340-32-7
PubChem CID	135567383
ChemSpider	65323639
Chemical and physical data
Formula	C17H15NO2
Molar mass	265.312 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=C(C=CC(=C1)C2=C3C=CC(=CC3=NC=C2)OC)O
InChI InChI=1S/C17H15NO2/c1-11-9-12(3-6-17(11)19)14-7-8-18-16-10-13(20-2)4-5-15(14)16/h3-10,19H,1-2H3 Key:HNYBTVKYLVLWCB-UHFFFAOYSA-N

See also

• CU-CPT4a
• Imiquimod
• Motolimod